215 related articles for article (PubMed ID: 35343371)
1. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.
Alwhaibi A; Alsanea S; Almadi B; Al-Sabhan J; Alosaimi FD
Aging Male; 2022 Dec; 25(1):101-124. PubMed ID: 35343371
[No Abstract] [Full Text] [Related]
2. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.
Siebert AL; Lapping-Carr L; Morgans AK
Eur Urol Focus; 2020 Nov; 6(6):1170-1179. PubMed ID: 32690473
[TBL] [Abstract][Full Text] [Related]
4. Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
Qazi SU; Altaf Z; Zafar M; Tariq MA; Khalid A; Kaleem A; Saad E; Qazi S
Prostate; 2024 May; 84(6):525-538. PubMed ID: 38372065
[TBL] [Abstract][Full Text] [Related]
5. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
6. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
[TBL] [Abstract][Full Text] [Related]
7. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
Tully KH; Nguyen DD; Herzog P; Jin G; Noldus J; Nguyen PL; Kibel AS; Sun M; McGregor B; Basaria S; Trinh QD
Eur Urol Oncol; 2021 Feb; 4(1):66-72. PubMed ID: 31624049
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Lee M; Jim HS; Fishman M; Zachariah B; Heysek R; Biagioli M; Jacobsen PB
Psychooncology; 2015 Apr; 24(4):472-7. PubMed ID: 24924331
[TBL] [Abstract][Full Text] [Related]
10. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
13. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
15. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
Nead KT; Sinha S; Yang DD; Nguyen PL
Urol Oncol; 2017 Nov; 35(11):664.e1-664.e9. PubMed ID: 28803700
[TBL] [Abstract][Full Text] [Related]
16. Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians.
Elbourne H; Soo WK; O'Reilly V; Moran A; Steer CB
Support Care Cancer; 2022 Feb; 30(2):1379-1389. PubMed ID: 34519868
[TBL] [Abstract][Full Text] [Related]
17. A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.
Garland SN; Savard J; Eisel SL; Wassersug RJ; Rockwood NJ; Thoms J; Jim HSL; Gonzalez BD
Cancer; 2021 Dec; 127(24):4656-4664. PubMed ID: 34411294
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
19. Examining the impact of androgen deprivation therapy, masculine self-esteem, and psychological flexibility on distress and quality of life in men with prostate cancer.
Chowdhury E; Horrocks T; McAteer G; Gillanders D
Psychooncology; 2024 Jan; 33(1):e6277. PubMed ID: 38282234
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
